Eli Lilly & Co. (LLY) News and Global Pharmaceutical Innovation Updates
1,144.8
10.2400
0.89 %
Real-time price
13:06
USD
Daily range
1137.44
1148.51
1148.51
Weekly range
1146.47
1230.00
1230.00
LLY shares edge lower amid overbought signals on Bull/Bear Power indicator: weekly report
Eli Lilly and Company (LLY) is currently trading at $1,139.09, well above its weekly MA-20 ($1,032.45), MA-50 ($965.13), and MA-200 ($723.25), confirming a sustained ...
Eli Lilly stock drops around 2.5% after recent Alzheimer's drug data release and ongoing lobbying activity
Eli Lilly and Company (LLY) slid 2.47% as profit-taking and near-term seller pressure followed recent corporate event milestones, including its latest data release in Alzheimer's treatment and ...
Eli Lilly shares technical analysis: Sellers keep control of short-term trend
Eli Lilly (LLY) stock is trading at $1,148, marking a daily decline of 2.87%. The shares currently sit below their key moving averages, reflecting persistent downside ...
LLY slides around 2.5% as technical uptrend meets selling on fresh corporate news
Eli Lilly and Company (LLY) fell 2.48% after opening lower, with selling pressure following recent corporate news flows. The move is contradicted by the bullish technical structure, as the stock ...
Eli Lilly shares rise around 2.5% as positive retatrutide trial data and bullish technicals drive gains
Eli Lilly and Company (LLY) advanced 2.45% after new late-stage clinical trial data on retatrutide for obesity and obstructive sleep apnea fueled renewed buying interest. The move is supported by ...
Eli Lilly shares gain nearly 3% after DKSH deal boosts Hong Kong and Macau pharma sales
Eli Lilly (LLY) stock is trading at $1,235, marking a daily gain of 2.84%. The price remains above its key moving averages, suggesting continued positive momentum in the ...
Eli Lilly shares advance with price holding over all major moving averages: weekly forecast
Eli Lilly and Company (LLY) closed the week at $1,234.23, marking a rise of $25.80 or 2.12% over the past seven days. The asset is solidly positioned above its weekly ...
Medicare trial expands GLP-1 obesity drug coverage for older Americans
A new Medicare pilot starting Wednesday lowers monthly out-of-pocket costs for some obesity medicines to about $50, widening access for older Americans who were largely excluded from coverage. The ...
LLY stock holds firm above MA-50 at $950 after Purdue partnership extension: weekly analysis
Eli Lilly and Company (LLY) ended the week at $1,192.26, posting a decline of $24.65 (1.58%) for the period. The price remains significantly above its weekly MA-20 at ...
Medicare launches obesity drug coverage, opening new market for Novo Nordisk and Eli Lilly
Eligible Medicare beneficiaries gain access to GLP-1 obesity drugs from July 1 through a temporary Bridge program, marking the first time the federal program covers these medicines for weight ...
Eli Lilly, Regeneron join FDA pilot to speed U.S. drug plant reviews
The U.S. Food and Drug Administration is selecting an initial group of drugmakers for a pilot program aimed at shortening the review process for new domestic pharmaceutical manufacturing sites. ...
Medicare obesity drug coverage expansion faces awareness gap among U.S. seniors
A major Medicare policy change is opening obesity drug access to eligible older Americans from July 1 at a $50 monthly copay. The rollout broadens access to Novo Nordisk and Eli Lilly treatments, ...
Jaypirca EU approval recommendation for leukemia lifts Eli Lilly stock above $1,184
Eli Lilly (LLY) stock is trading at $1,184, up 5.08% on the day and posting strong gains near the session highs. The price stands well above its key moving averages, ...
Eli Lilly shares jump as stock buying pressure builds
Eli Lilly and Company (LLY) surged 5.83% after the company advanced its expansion strategy by launching Tanstrive, a RET-targeted cancer therapy, in India following regulatory approval. The move ...
Employer health plans reassess GLP-1 pill coverage as obesity drug costs stay high
Large employers are becoming more cautious about covering new GLP-1 weight-loss pills as demand for obesity treatment rises. Oral products from Novo Nordisk and Eli Lilly are expected to widen ...
Eli Lilly stock consolidates near $1,100 with continued bullish momentum supported by MACD: weekly forecast
Eli Lilly and Company (LLY) ended the week at $1,106.92, marking a gain of $7.44 or 0.59% over the last seven days. The price remains firmly above the weekly MA-20 at ...
Eli Lilly expands AI drug discovery investment to diversify beyond weight-loss franchise
Rising cash flow from Eli Lilly's blockbuster obesity and diabetes medicines is funding a broader push into artificial intelligence and biotech deals as the company prepares for patent expiries in ...
Eli Lilly expands dealmaking in pain drugs as Broadcom insider buy signals confidence
Investors are rotating across sectors after a sharp technology rally, while healthcare and financial stocks draw attention alongside falling oil prices and steady rate expectations. In that ...
Eli Lilly stock edges lower while buyers defend $1,111 support: weekly analysis
Eli Lilly and Company (LLY) is currently trading at $1,124.43, maintaining a strong bullish profile well above the weekly MA-20 ($1,003.56), MA-50 ($933.13), and MA-200 ...
Eli Lilly shares dip amid rising selling pressure
Eli Lilly and Company (LLY) is trading at $1,135.05, above the 20-day ($1,079.18), 50-day ($992.89), and 200-day ($956.36) moving averages. Today’s price is down 2.13%, closing near the low end ...
Why is Eli Lilly stock up today?
Eli Lilly and Company (LLY) is currently trading at $1,160.25, up $23.88, or 2.10% on the day. The asset remains well above its 20-day ($1,071.94), 50-day ($988.08), and 200-day ($954.04) moving ...
